Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Interest Expenses (2016 - 2025)

Abeona Therapeutics has reported Interest Expenses over the past 14 years, most recently at $884000.0 for Q4 2025.

  • Quarterly results put Interest Expenses at $884000.0 for Q4 2025, down 18.3% from a year ago — trailing twelve months through Dec 2025 was $3.7 million (down 11.12% YoY), and the annual figure for FY2025 was $3.7 million, down 11.12%.
  • Interest Expenses for Q4 2025 was $884000.0 at Abeona Therapeutics, down from $901000.0 in the prior quarter.
  • Over the last five years, Interest Expenses for ABEO hit a ceiling of $1.5 million in Q2 2021 and a floor of $53000.0 in Q4 2021.
  • Median Interest Expenses over the past 5 years was $783500.0 (2021), compared with a mean of $637900.0.
  • Biggest five-year swings in Interest Expenses: plummeted 96.18% in 2021 and later surged 949.52% in 2024.
  • Abeona Therapeutics' Interest Expenses stood at $53000.0 in 2021, then soared by 235.85% to $178000.0 in 2022, then crashed by 38.76% to $109000.0 in 2023, then surged by 892.66% to $1.1 million in 2024, then dropped by 18.3% to $884000.0 in 2025.
  • The last three reported values for Interest Expenses were $884000.0 (Q4 2025), $901000.0 (Q3 2025), and $957000.0 (Q2 2025) per Business Quant data.